Emma Dean
Emma Dean
Director Physician, Early Phase Oncology | AstraZeneca
Verified email at
Cited by
Cited by
AKT inhibition in solid tumors with AKT1 mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251, 2017
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
DG Rothwell, M Ayub, N Cook, F Thistlethwaite, L Carter, E Dean, N Smith, ...
Nature medicine 25 (5), 738-743, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
JHL Fok, A Ramos-Montoya, M Vazquez-Chantada, PWG Wijnhoven, ...
Nature communications 10 (1), 5065, 2019
Biomarkers of apoptosis
TH Ward, J Cummings, E Dean, A Greystoke, JM Hou, A Backen, ...
British journal of cancer 99 (6), 841-846, 2008
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
JS De Bono, N Concin, DS Hong, FC Thistlethwaite, JP Machiels, ...
The lancet oncology 20 (3), 383-393, 2019
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
RL Lloyd, PWG Wijnhoven, A Ramos-Montoya, Z Wilson, G Illuzzi, ...
Oncogene 39 (25), 4869-4883, 2020
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
E Dean, MR Middleton, T Pwint, H Swaisland, J Carmichael, ...
British journal of cancer 106 (3), 468-474, 2012
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
G Falchook, J Infante, HT Arkenau, MR Patel, E Dean, E Borazanci, ...
EClinicalMedicine 34, 2021
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014
B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ...
Clinical cancer research 21 (15), 3412-3419, 2015
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
JC Soria, HK Gan, SP Blagden, R Plummer, HT Arkenau, M Ranson, ...
Annals of Oncology 27 (12), 2268-2274, 2016
An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib
J Mateo, V Moreno, A Gupta, SB Kaye, E Dean, MR Middleton, ...
Targeted oncology 11, 401-415, 2016
A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers
U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ...
Clinical Cancer Research 24 (9), 2050-2059, 2018
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer
E Dean, D Jodrell, K Connolly, S Danson, J Jolivet, J Durkin, S Morris, ...
Journal of clinical oncology 27 (10), 1660-1666, 2009
IAPs as a target for anticancer therapy
S Danson, E Dean, C Dive, M Ranson
Current Cancer Drug Targets 7 (8), 785-794, 2007
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
J Cortes, K Tamura, DJ DeAngelo, J De Bono, D Lorente, M Minden, ...
British journal of cancer 118 (11), 1425-1433, 2018
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine±cisplatin in patients with advanced solid tumours
MR Middleton, E Dean, TRJ Evans, GI Shapiro, J Pollard, BS Hendriks, ...
British journal of cancer 125 (4), 510-519, 2021
Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic
EJ Dean, M Ranson, F Blackhall, SV Holt, C Dive
Cancer treatment reviews 33 (2), 203-212, 2007
Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
F Andre, M Ranson, E Dean, A Varga, R Van der Noll, PK Stockman, ...
Cancer research 73 (8_Supplement), LB-145-LB-145, 2013
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy
R Kim, M Kwon, M An, ST Kim, SA Smith, AB Loembé, PGS Mortimer, ...
Annals of Oncology 33 (2), 193-203, 2022
X-linked inhibitor of apoptosis protein as a therapeutic target
EJ Dean, M Ranson, F Blackhall, C Dive
Expert opinion on therapeutic targets 11 (11), 1459-1471, 2007
The system can't perform the operation now. Try again later.
Articles 1–20